Verona Pharma Plc ADR (NASDAQ: VRNA) kicked off on Tuesday, up 2.96% from the previous trading day, before settling in for the closing price of $72.58. Over the past 52 weeks, VRNA has traded in a range of $11.39-$74.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -39.77%. While this was happening, its average annual earnings per share was recorded 153.85%. With a float of $76.70 million, this company’s outstanding shares have now reached $85.13 million.
Considering the fact that the conglomerate employs 209 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 94.72%, operating margin of -116.27%, and the pretax margin is -131.25%.
Verona Pharma Plc ADR (VRNA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 9.90%, while institutional ownership is 87.07%. The most recent insider transaction that took place on May 20 ’25, was worth 1,451,600. Before that another transaction happened on May 15 ’25, when Company’s General Counsel sold 80,000 for $8.57, making the entire transaction worth $685,600. This insider now owns 359,999 shares in total.
Verona Pharma Plc ADR (VRNA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 153.85% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Take a look at Verona Pharma Plc ADR’s (VRNA) current performance indicators. Last quarter, stock had a quick ratio of 8.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 53.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.00 in the next quarter and is forecasted to reach 1.08 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Compared to the last year’s volume of 1.47 million, its volume of 1.13 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 95.19%. Additionally, its Average True Range was 3.58.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 97.69%, which indicates a significant increase from 95.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.60% in the past 14 days, which was lower than the 57.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $64.46, while its 200-day Moving Average is $46.73. Nevertheless, the first resistance level for the watch stands at $76.08 in the near term. At $77.44, the stock is likely to face the second major resistance level. The third major resistance level sits at $79.40. If the price goes on to break the first support level at $72.76, it is likely to go to the next support level at $70.80. Now, if the price goes above the second support level, the third support stands at $69.44.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
The company with the Market Capitalisation of 6.36 billion has total of 81,080K Shares Outstanding. Its annual sales at the moment are 42,280 K in contrast with the sum of -173,420 K annual income. Company’s last quarter sales were recorded 76,260 K and last quarter income was -16,320 K.
